We explored the association of C-peptide (marker of secreted insulin), proinsulin and proinsulin ⁄C-peptide ratio (PI/C) (markers of beta-cell endoplasmic reticulum [ER] stress) with undercarboxylated (uOC) and carboxylated osteocalcin (cOC) and their ratio (uOC/cOC) in children with recently diagnosed type 1 (T1D) or type 2 diabetes (T2D), and the correlation of these variables with partial remission (PR) in children with T1D.
| INTRODUC TI ON
Paediatric diabetes incidence has increased significantly in recent years. Worldwide, type 1 diabetes (T1D) increased 2.8% from 1990 to 1999, 1 and the current T1D prevalence in the United States is 0.3% by 18 years of age. 2 Type 2 diabetes (T2D) prevalence in young people parallels the increase in obesity rates, and similarly increases with age 3, 4 ; however, T2D in youth has been proposed to represent a distinct disease state from both T1D and adult-onset T2D, including a faster decline in β (beta)-cell function, and accelerated development of microvascular complications. 5, 6 Insulin resistance (IR) and transient compensatory hyperinsulinaemia precede and predict T2D. 7 In T1D, progressive loss of β-cell function and mass are the key features of the disease, but insulin resistance can also occur in both youth 8, 9 and adults, 10 particularly related to longer disease duration and/or higher body fat mass. 11 Interestingly, one study found that while IR was identified in T1D youth, it did not share similar features with metabolic syndrome as found in T2D, and instead represented a unique phenotype. 9 Insufficient metabolic control resulting in chronic glucose toxicity and impaired muscle metabolism could be the primary cause of insulin resistance in T1D. 8 The physiological increase in body weight with age and development requires a matched increase in β-cell mass and circulating levels of insulin in order to maintain appropriate glucose metabolism. 12 Insulin deficiency is present in all diabetes subtypes, and while β-cell mass loss in T1D is 70%-100%, 13 it ranges from 0% to 65% in adults with T2D. 14, 15 The link between β-cell mass loss versus dysfunction is diverse and still incompletely elucidated in the T2D context. 14, 15 More perplexing, perhaps, is the relatively large variability in assessed β-cell mass from adult cadaveric samples without diabetes, 15 as well as in both lean and obese individuals. 15, 16 There is no way to conclusively quantitate β-cell mass in the living patient. Moreover, the timing and extent of this loss in the paediatric population with new-onset diabetes is doubly unknown, particularly as other influences including diabetes subtype, age at diagnosis, BMI and weight management approaches, sexual maturation and hormonal changes, and psychosocial determinants complicate treatment decisions in this sensitive cohort, 17 and which are even further confounded by dynamic insulin requirements during the "honeymoon phase" of diabetes progression, transient diabetes remission by β-cell "rest" following exogenous insulin commencement, and timing of initiation of advanced insulin delivery systems including pumps and CGM. 18, 19 Therefore, layers of complexity exist with regard to β-cell mass and function loss, not least being the variable amount of endogenous starting material before pathological circumstances further diminish β-cell reserve.
C-peptide level is considered the best surrogate marker of β-cell function. 20 Elevations in the fasting proinsulin-to-C-peptide ratio (PI:C) have been shown to precede the onset of T1D and are indicators of β-cell endoplasmic reticulum [ER] stress 21, 22 and persist after diagnosis. Furthermore, T1D patients in partial remission (PR), defined as insulin dose-adjusted HbA1c (IDAA1c) ≤9, 23 demonstrate higher proinsulin levels in the first 6 and 12 months following diagnosis relative to patients who did not remit, and thus, higher proinsulin was positively associated with C-peptide, suggesting residual β-cell function and simultaneous β-cell distress. 24 The osteoblast-derived hormone osteocalcin (OC) has been implicated as a link between the skeleton and endocrine pancreas' role in glucose regulation, stemming from the observation that knockout mice lacking the OCN gene have glucose intolerance, insulin resistance, impaired insulin secretion and abnormal accumulation of visceral fat. 25 Importantly, there is an established feed-forward regulation loop linking insulin, bone resorption and osteocalcin. 26, 27 Our group has previously demonstrated that OC is positively associated with insulin sensitivity and β-cell function in animal models in vivo, and in human islets, respectively, 28, 29 and others have shown that OC increased β-cell proliferation in mice through its receptor, GPRC6a. 30 During synthesis, OC undergoes a vitamin K-dependent carboxylation, which is incorporated into bone matrix, 31 whereas the undercarboxylated form of OC (uOC) has been shown to be involved in energy metabolism and insulin action, and was proposed to be the biologically active form of the hormone. 32 Higher uOC was correlated with improved peripheral and hepatic insulin sensitivity and β-cell function in nondiabetic, overweight adults. 32 In a model of paediatric obesity and metabolic syndrome (MetS), decreased OC was shown to correlate with IR, 33 and in adult patients with T2D, and it was purported that uOC can predict insulin secretion ability. 34 We have previously shown an inverse relationship between uOC and haemoglobin A1c (A1c) in a paediatric population recently diagnosed with diabetes. 35 However, the potential correlation of retained β-cell function by C-peptide and proinsulin values, uOC, PR status in T1D, IR and diabetes subtype in this population is unknown.
The objectives of this analysis were to evaluate the relationships between C-peptide, proinsulin, uOC and cOC levels in children with recently diagnosed T1D and T2D. Better understanding of the factors associated with β-cell function early after the diagnosis of diabetes may improve current approaches for treatment paradigms.
| MATERIAL S AND ME THODS

| Patients and data collection
We prospectively evaluated children who presented with newly diagnosed diabetes at Texas Children's Hospital (Houston, Texas) between October 2010 and October 2011, and followed until October 2014, as previously described. [36] [37] [38] Diabetes type (e.g. T1D and T2D) was classified based on clinical criteria. 39 Cases of secondary diabetes Disease Control and Prevention criteria. 40 Obesity was defined as BMI ≥ 95th gender-specific and age-specific BMI centile, and overweight as BMI centile ≥ 85th to < 95th. Diabetic ketoacidosis (DKA) was defined by venous blood pH < 7.3 and bicarbonate < 15 mEq/L.
| Laboratory methods
| Islet autoantibodies
GAD65, ICA512/IA2 and ZnT8 autoantibodies were measured by the radioligand binding assay as previously described 41, 42 as standardized in the International Combined Autoantibody Workshop. 43 The cut-off for GAD65 antibody (Ab) positivity was set at 45U/ml and established as the 98th percentile for healthy controls. Samples were considered ICA512/IA2 autoantibody (ICA512/IA2Ab) positive ≥ 98th centile for healthy controls (30 RU/mL). For ZnT8 autoantibodies (ZnT8Ab), a cut-off was set at 15 RU/mL for ZnT8Arg and 26 RU/mL for ZnT8Trp based on the 98th centile observed in 50 healthy human control sera. Samples were considered ZnT8Ab positive if binding to either ZnT8Arg or ZnT8Trp was detected. The GAD65Ab assay showed 86% sensitivity and 93% specificity, and the ICA512/ IA2Ab assay showed 66% sensitivity and 98% specificity, as defined by the Diabetes Autoantibody Standardization Program (DASP) workshop, 44 in which we participated. ZnT8 autoantibodies were not included in the workshop. Insulin autoantibodies were measured by the Quest Diagnostics Nichols Institute (San Juan Capistrano, CA, USA) by radioimmunoassay (RIA) with clinical sensitivity and specificity of 50% and 99%, respectively (positivity > 0.4 U/mL).
| OC measurements
Serum cOC and uOC levels were measured by enzyme immunoassays (Human Gla-OC High Sensitive EIA Kit (MK111) and Glu-OC EIA Kit (MK118), Takara Bio Inc). The range of the assays is 0.5-16 and 0.25-8 ng/mL, respectively, with assay sensitivity of 0.5 ng/mL for both kits.
| Proinsulin and C-peptide measurements
Random serum proinsulin was measured by ELISA (Human Total Proinsulin ELISA, ALPCO). Random serum C-peptide levels were obtained at diagnosis and measured by highly specific RIA (Human C-Peptide RIA Kit, Millipore Research Inc).
| Statistical analyses
The distribution of the continuous variables was evaluated for nor- and age, sex, race/ethnicity and BMI percentile at V1 revealed that older age and higher BMI were significantly correlated with higher levels of C-peptide (β = 0.13, P = .001; and β = 0.02, P = .001, respectively) ( Table 3) , implying higher retained β-cell function. Moreover, older age and higher BMI were significantly correlated with a lower proinsulin/C-peptide ratio (β = −0.12, P = .001; and β = −0.01, P = .02, respectively) ( Table 3 ). However, there was no significant association of these factors in children with T2D (n = 20) (Table 3 ).
| RE SULTS
There was a positive association between C-peptide and non-Hispanic White race/ethnicity in T1D and T2D patients ( Table 3) ; this association was additionally shown by univariate GLM analysis in the same cohorts (Table S1 ). In T1D patients only, the univariate GLM analysis showed similar, significant associations between BMI at V1 with proinsulin (P = <0.001) and C-peptide (P = <0.001) (Table S1) , as well as significant associations of age at diagnosis (P = .001) and the proinsulin/C-peptide ratio (P = .02) (Table S1 ).
In children with T1D who had IDAA1c data available at V1 (n = 48), V2 (n = 33), and V3 (n = 36), the association of partial remission with proinsulin, C-peptide, proinsulin/C-peptide ratio, uOC, cOC and uOC/cOC levels measured at V1 was examined. Mixedeffects logistic regression modelling was performed to evaluate the association of IDAA1c ≤ 9/>9 over time (from visit 1 through visit 3)
as a dependent variable and individual laboratory parameters as independent variables (cOC, uOC, uOC/cOC ratio, proinsulin (pmol/L), C-peptide (ng/mL), proinsulin/C-peptide ratio). After adjusting for age and BMI percentile, the analyses showed a significant correlation of C-peptide at V1 with IDAA1c ≤ 9 (Table 4) , while neither proinsulin nor proinsulin/C-peptide ratio was significantly correlated.
| D ISCUSS I ON
The main finding of this study was that the uOC/cOC ratio was significantly correlated with C-peptide in children with new onset of diabetes in the early postdiagnosis time period, whether diagnosed with T1D and presenting with DKA at diagnosis, or T2D. We have previously shown that uOC and the uOC/cOC ratio are inversely correlated with A1c in children with recent-onset diabetes, 35 that uOC correlates with endogenous insulin presence as evidenced by C-peptide levels. These assertions have been supported by multiple other reports, showing an association between serum OC level and insulin sensitivity and secretion in patients without 45 and with T2D, 34, 46 as well as improvements in cardiovascular and glycaemic health. 47 Others have shown an inverse relationship of OC with hyperglycaemia in adults, 48 and of OC with BMI in overweight 49 Understanding variable factors of β-cell dysfunction and loss will help with prognosis and treatment decisions in all diabetes subtypes. In T1D, lack of residual β-cell function is associated with poor glucose control, 37 and is associated with diabetic ketoacidosis (DKA), which is life-threatening. In T2D, C-peptide levels also have clinical significance, as a study in T2D youth aged 16.1 ± 2.5 years with a median disease duration of 2.4 years showed that a decline in C-peptide levels was associated with deterioration of metabolic control and the consequent need for insulin therapy. 53 Of note, while uOC/cOC significantly correlated with C-peptide levels at diagnosis in children with T2D, children diagnosed with T1D and who presented with DKA at diagnosis showed a significant correlation with uOC/cOC at V1. These data suggest that because of the differences in β-cell function at diagnosis between type 1 and type 2, uOC and uOC/cOC ratio reflect differences in β-cell mass and islet functional status. That is, in newly diagnosed T2D children, uOC and uOC/cOC ratio are associated with glycaemic control and insulin sensitivity, whereas early after T1D diagnosis, uOC and uOC/ cOC ratio are associated with residual β-cell functional mass. This differential temporal responses could be the result of β-cell "rest"
following appropriate treatment initiation. 54 We did find a significant association of non-Hispanic White race/ethnicity with C-peptide in both diabetes subtypes. Additionally, in children with T1D, older age and higher BMI were significantly correlated with higher levels of C-peptide and thus lower proinsulin-to-C-peptide ratio. This finding is consistent with prior reports that C-peptide increases with age and BMI, possibly reflecting the increase in insulin secretion in response to puberty, ageing and obesity. 12, 55 We also noted that proinsulin was positively associated with BMI in participants with T1D, which was consistent with a higher C-peptide, suggesting that the lower proinsulin-to-C-peptide ratio implies no increase in low levels of β-cell ER stress, unlike evidence of elevations in proinsulin-to-C-peptide ratio preceding the onset of T1D proposed by others. 22 On the contrary, this evidence suggests that the β cell is able to process available endogenous proinsulin efficiently in the prediagnosis timeframe, supporting data from Brissova et al demonstrating that remnant β cells in T1D islets maintain regulated insulin secretion. 56 Furthermore, there was no significant finding of insulin resistance in the new-onset T1D subset by proinsulin or by correlation with uOC, which we speculate could occur only after longer disease duration, as Sims et al demonstrated that proinsulin secretion is a persistent feature of T1D. 21 These conflicting data may further confound data interpretation and require further investigation. Moreover, as we found no significant correlation of C-peptide levels with either BMI or age in the T2D cohort, future studies with larger sample size are necessary to evaluate this relationship, as others have shown that chronic hyperglycaemia is inversely correlated with circulating OC levels in adult T2D patients. 48 In our study, children specifically with T1D who had IDAA1c ≤ 9 at V1 to V3 had significantly higher levels of C-peptide at V1, after adjustment for age and BMI. This observation is consistent with prior reports of IDAA1c as a marker of partial diabetes remission and indicates that endogenous insulin production is an important component of the partial remission metric. Neither proinsulin nor the proinsulin/C-peptide ratio was significantly correlated with IDAA1c ≤ 9 at V1-V3, suggesting that ER stress does not change in that discrete period of T1D disease progression. However, IDAA1c
as a metric for partial diabetes remission does not account for carbohydrate intake, which is an inherent component of total daily insulin dosage. Instead, these data show support for monitoring endogenous C-peptide levels, and thus retained β-cell function, after diabetes diagnosis in children as part of a full clinical evaluation. The potential relationship between C-peptide, undercarboxylated osteocalcin and age at diagnosis with long-term outcomes and complication risk remains to be elucidated.
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